Paper Details

  1. Home
  2. Paper Details

Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.

Author: ClampAndrew, CookAdrian, GohBoon Cher, GohRobby M, HuangRuby Yun-Ju, JamesElizabeth, NgoiNatalie Yl, SoonYu Yang, SynNicholas Lx, TanDavid Sp

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study explores the optimal dosing schedule of paclitaxel when combined with carboplatin as first-line treatment for epithelial ovarian cancer. Intravenous carboplatin and paclitaxel are widely accepted as standard treatment, but there is conflicting evidence regarding the best paclitaxel dosing schedule.
Paper Details　
Original Abstract of the Article :
Epithelial ovarian cancer is the sixth most common cancer worldwide: 295,414 new cases were diagnosed in 2018, with 184,799 deaths. The lack of an effective screening strategy has led to the majority of women being diagnosed at an advanced stage. For these women, intravenous carboplatin combined wit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859866/

データ提供：米国国立医学図書館（NLM）

Paclitaxel Dosing for Ovarian Cancer: Weekly vs. Tri-weekly

Epithelial ovarian cancer, a significant global health concern, often requires chemotherapy with carboplatin and paclitaxel. This study delves into the optimal dosing schedule for paclitaxel in this context, exploring whether weekly or tri-weekly administration is more effective. The research highlights the need for further investigation to clarify the optimal dosing strategy for paclitaxel in the treatment of ovarian cancer.

Finding the Right Dose: A Balance in Cancer Treatment

This research underscores the importance of finding the right balance in chemotherapy dosing. Much like a camel adjusting its pace based on the desert terrain, optimizing paclitaxel dosing requires a careful consideration of factors such as effectiveness and potential side effects. The study's findings demonstrate that further investigation is necessary to determine the optimal dosing schedule that provides the best therapeutic outcome for patients with ovarian cancer.

Navigating Treatment Options for Ovarian Cancer

This study serves as a reminder that the treatment of cancer is complex and involves navigating multiple factors. The research highlights the importance of personalized medicine, where treatment decisions are tailored to the individual patient's needs and characteristics. It is essential to consult with healthcare professionals to explore all available treatment options and make informed decisions based on individual circumstances.

Dr. Camel's Conclusion

This study emphasizes the ongoing need for research to refine treatment strategies for ovarian cancer. It highlights the importance of finding the optimal balance between effectiveness and safety in chemotherapy dosing. As we continue to explore new approaches, we can hope for improved outcomes and a better quality of life for those facing this challenging disease.

Date :
  1. Date Completed 2022-03-01
  2. Date Revised 2023-11-15
Further Info :

Pubmed ID

35188221

DOI: Digital Object Identifier

PMC8859866

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.